BerandaMANKIND • NSE
add
Mankind Pharma Ltd
Tutup sebelumnya
₹2.328,70
Rentang hari
₹2.275,00 - ₹2.351,70
Rentang tahun
₹1.901,05 - ₹3.054,80
Kapitalisasi pasar
946,02 M INR
Volume Rata-Rata
681,80 rb
Rasio P/E
45,11
Hasil dividen
-
Bursa utama
NSE
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (INR) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 32,30 M | 23,90% |
Biaya operasional | 16,57 M | 29,21% |
Laba bersih | 3,80 M | -16,20% |
Margin laba bersih | 11,77 | -32,40% |
Penghasilan per saham | 9,44 | -16,53% |
EBITDA | 7,34 M | 27,38% |
Tarif pajak efektif | 22,68% | — |
Neraca
Total aset
Total liabilitas
| (INR) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 47,27 M | 103,22% |
Total aset | — | — |
Total liabilitas | — | — |
Total ekuitas | 107,89 M | — |
Saham yang beredar | 402,36 jt | — |
Harga terhadap nilai buku | 8,83 | — |
Tingkat pengembalian aset | — | — |
Tingkat pengembalian modal | 14,14% | — |
Arus Kas
Perubahan kas bersih
| (INR) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 3,80 M | -16,20% |
Kas dari operasi | — | — |
Kas dari investasi | — | — |
Kas dari pembiayaan | — | — |
Perubahan kas bersih | — | — |
Arus kas bebas | — | — |
Tentang
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
Didirikan
1991
Situs
Karyawan
19.540
